Merck & Co. Share Price (NYSE: MRK)

$85.47

▲

1.35

(1.6%)

Last updated on September 3, 2025 at 1:29 am IST

$₹

Check the interactive Merck & Co. Stock chart to analyse performance

Merck & Co. stock performance

as on September 3, 2025 at 1:29 am IST

Today's Low:$84.45
Today's High:$85.47
$85.47
1.2%
Downside
Day's Volatility :1.2%
Upside
0.0%
52 Weeks Low:$73.31
52 Weeks High:$120.30
$85.47
14.23%
Downside
52 Weeks Volatility :39.06%
Upside
28.95%

Merck & Co. Stock Returns

Period	Merck & Co. Inc.	Sector (Health Care)	S&P500
3 Months	7.47%	3.3%	8.2%
6 Months	-9.73%	-8.1%	10.4%
1 Year	-27.84%	-12.4%	16.8%
3 Years	-2.66%	10.0%	64.6%

Merck & Co. Inc. Key Stats

Check Merck & Co. key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$84.12
Open	$84.535
Today's High	$85.47
Today's Low	$84.445
Market Capitalization	$210.1B
Today's Volume	$10.9M
52 Week High	$120.3
52 Week Low	$73.31
Revenue TTM	$63.6B
EBITDA	$28.3B
Earnings Per Share (EPS)	$6.49
PE Ratio	12.96
Dividend Yield	3.8%
Profit Margin	25.79%
Quarterly Earnings Growth YOY	-0.18%
Return On Equity TTM	35.42%

Stock Returns calculator for Merck & Co. Stock including INR - Dollar returns

The Merck & Co. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Merck & Co. investment value today

Current value as on today

₹78,320

Returns

₹21,680

(-21.68%)

Returns from Merck & Co. Stock

₹26,686 (-26.69%)

Dollar Returns*

₹5,006 (+5.01%)

Indian investors sentiment towards Merck & Co. Stock

-31.76%

Period: Aug 3, 2025 to Sep 2, 2025. Change in 30 Days versus previous period

Investment in Merck & Co. Shares from India has dropped by -31.76% over the past 30 days, indicating reduced transactional activity.

-20%

Period: Aug 3, 2025 to Sep 2, 2025. Change in 30 Days versus previous period

Search interest for Merck & Co. Stock from India on INDmoney has decreased by -20% in the last 30 days, reflecting a downward trend in search activity.

Indian Mutual Funds that invest in Merck & Co. Stock

Name	Shares Held	Change in Shares	% of Assets
Axis Innovation Fund Direct Growth	5034	-74.30	0.29%
Motilal Oswal S&P 500 Index Fund Direct Growth	20297	-374.48	0.36%
ICICI Prudential US Bluechip Equity Fund Direct Plan Growth	60800	8007.97	1.28%
Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund Direct Growth	3968	0.00	1.64%

Global Institutional Holdings in Merck & Co. Inc.

Name
Holdings %
Name
Holdings %
Vanguard Group Inc
10.13%
BlackRock Inc
9.02%
State Street Corp
4.83%
Wellington Management Company LLP
3.08%
Geode Capital Management, LLC
2.39%
Charles Schwab Investment Management Inc
2.16%

Analyst Recommendation on Merck & Co. Stock

Rating

Trend

Buy

87%Buy

12%Hold

0%Sell

Based on 31 Wall street analysts offering stock ratings for Merck & Co.(by analysts ranked 0 to 5 stars)

Merck & Co. Share Price Target

What analysts predicted

Upside of 17.48%

Target:

$100.41

Current:

$85.47

Merck & Co. share price target is $100.41, a slight Upside of 17.48% compared to current price of $85.47 as per analysts' prediction.

Merck & Co. Stock Insights

Price Movement
In the last 6 months, MRK stock has moved down by -9.7%
Increasing Revenue
Merck & Co. Inc. has shown positive revenue performance over the last two quarters. The company's revenue increased from $15.52 billion to $15.80 billion, reflecting an average growth of 1.8% per quarter.
Decreasing Net Profit
Merck & Co. Inc. has experienced a decline in its net profit over the last two quarters. The company's net profit dropped from $5.07 billion to $4.42 billion, averaging a decrease of 12.8% per quarter.
MRK vs ABBV (1 yr)
In the last 1 year, Abbvie Inc has given 6.4% return, outperforming this stock by 34.2%
MRK vs LLY (3 yr)
In the last 3 years, Eli Lilly And Company has given 54.4% return, outperforming this stock by 56.8%
Price to Sales
Merck & Co. Inc. has a Price-to-Sales Ratio of 3.4, meaning that investors are willing to pay $3.4 for every $1 of sales the company generates. In comparison, Abbvie Inc. has a higher Price-to-Sales Ratio of 6.4, where investors are paying $6.4 for every $1 of sales. This indicates that investors value Abbvie's sales more highly than those of Merck.

Merck & Co. Inc. Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$39.1B	↓ 7.5%
Net Income	$9.8B	↑ 58.25%
Net Profit Margin	25.16%	↑ 10.45%

	FY20	Y/Y Change
Revenue	$41.5B	↑ 6.13%
Net Income	$7.1B	↓ 28.2%
Net Profit Margin	17.02%	↓ 8.14%

	FY21	Y/Y Change
Revenue	$48.7B	↑ 17.31%
Net Income	$13.0B	↑ 84.65%
Net Profit Margin	26.79%	↑ 9.77%

	FY22	Y/Y Change
Revenue	$59.3B	↑ 21.72%
Net Income	$14.5B	↑ 11.27%
Net Profit Margin	24.49%	↓ 2.3%

	FY23	Y/Y Change
Revenue	$60.1B	↑ 1.4%
Net Income	$365.0M	↓ 97.49%
Net Profit Margin	0.61%	↓ 23.88%

	FY24	Y/Y Change
Revenue	$64.2B	↑ 6.74%
Net Income	$17.1B	↑ 4589.59%
Net Profit Margin	26.68%	↑ 26.07%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$15.8B	↑ 7.83%
Net Income	$4.8B	↓ 488.42%
Net Profit Margin	30.19%	↑ 38.57%

	Q2 FY24	Q/Q Change
Revenue	$16.1B	↑ 2.14%
Net Income	$5.5B	↑ 14.55%
Net Profit Margin	33.86%	↑ 3.67%

	Q3 FY24	Q/Q Change
Revenue	$16.7B	↑ 3.38%
Net Income	$3.2B	↓ 42.13%
Net Profit Margin	18.95%	↓ 14.91%

	Q4 FY24	Q/Q Change
Revenue	$15.6B	↓ 6.2%
Net Income	$3.7B	↑ 18.56%
Net Profit Margin	23.96%	↑ 5.01%

	Q1 FY25	Q/Q Change
Revenue	$15.5B	↓ 0.61%
Net Income	$5.1B	↑ 35.69%
Net Profit Margin	32.71%	↑ 8.75%

	Q2 FY25	Q/Q Change
Revenue	$15.8B	↑ 1.78%
Net Income	$4.4B	↓ 12.84%
Net Profit Margin	28.01%	↓ 4.7%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$27.1B	↓ 5.84%

	FY20	Y/Y Change
Profit	$27.9B	↑ 2.93%

	FY21	Y/Y Change
Profit	$35.1B	↑ 25.73%

	FY22	Y/Y Change
Profit	$41.9B	↑ 19.37%

	FY23	Y/Y Change
Profit	$44.0B	↑ 5.06%

	FY24	Y/Y Change
Profit	$49.0B	↑ 11.33%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$12.2B	↑ 8.37%

	Q2 FY24	Q/Q Change
Profit	$12.4B	↑ 1.08%

	Q3 FY24	Q/Q Change
Profit	$12.6B	↑ 1.7%

	Q4 FY24	Q/Q Change
Profit	$11.8B	↓ 6.21%

	Q1 FY25	Q/Q Change
Profit	$12.1B	↑ 2.66%

	Q2 FY25	Q/Q Change
Profit	$12.2B	↑ 1.15%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$13.4B	↑ 23.05%
Investing Cash Flow	$-2.6B	↓ 160.94%
Financing Cash Flow	$-8.9B	↓ 32.67%

	FY20	Y/Y Change
Operating Cash Flow	$10.3B	↓ 23.71%
Investing Cash Flow	$-9.4B	↑ 259.19%
Financing Cash Flow	$-2.8B	↓ 68.04%

	FY21	Y/Y Change
Operating Cash Flow	$14.1B	↑ 37.61%
Investing Cash Flow	$-16.6B	↑ 75.32%
Financing Cash Flow	$2.6B	↓ 191.56%

	FY22	Y/Y Change
Operating Cash Flow	$19.1B	↑ 35.34%
Investing Cash Flow	$-5.0B	↓ 70.04%
Financing Cash Flow	$-9.1B	↓ 451.68%

	FY23	Y/Y Change
Operating Cash Flow	$13.0B	↓ 31.89%
Investing Cash Flow	$-14.1B	↑ 183.93%
Financing Cash Flow	$-4.8B	↓ 47.25%

	FY24	Y/Y Change
Operating Cash Flow	$21.5B	↑ 65.06%
Investing Cash Flow	$-7.7B	↓ 45.08%
Financing Cash Flow	$-7.0B	↑ 46.2%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$3.1B	↑ 1156.1%
Investing Cash Flow	$-1.4B	↓ 2696.23%
Financing Cash Flow	$-2.8B	↑ 25.35%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$5.6B	↑ 82.43%
Investing Cash Flow	$-1.1B	↓ 22.31%
Financing Cash Flow	$1.2B	↓ 143.21%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$9.3B	↑ 64.82%
Investing Cash Flow	$-3.8B	↑ 259.68%
Financing Cash Flow	$-2.4B	↓ 299.42%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$3.5B	↓ 62.87%
Investing Cash Flow	$-1.4B	↓ 62.44%
Financing Cash Flow	$-3.0B	↑ 24.08%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$2.5B	↓ 27.54%
Investing Cash Flow	$-1.5B	↑ 2.98%
Financing Cash Flow	$-5.8B	↑ 91.26%

Merck & Co. Technicals Summary

Sell

Neutral

Buy

Merck & Co. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Merck & Co. Inc. Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Merck & Co. Inc.	5.33%	-9.73%	-27.84%	-2.66%	-1.31%
Eli Lilly And Company	-4.74%	-21.2%	-23.41%	138.77%	385.44%
Johnson & Johnson	3.58%	7.3%	5.99%	8.57%	19.23%
Novo Nordisk A/s	15.67%	-37.86%	-58.56%	9.01%	73.43%
Abbvie Inc	6.7%	-0.54%	6.43%	52.92%	129.02%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Merck & Co. Inc.	12.96	12.96	0.83	8.93	0.35	0.13	0.04	19.57
Eli Lilly And Company	47.85	47.85	1.06	22.83	0.86	0.17	0.01	20.38
Johnson & Johnson	18.97	18.97	1.08	10.85	0.3	0.08	0.03	32.6
Novo Nordisk A/s	14.51	14.51	1.67	24.83	0.79	0.22	0.03	37.82
Abbvie Inc	100.19	100.19	0.44	11.97	1.13	0.09	0.03	-0.1

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Merck & Co. Inc.	Buy	$210.1B	-1.31%	12.96	25.79%
Eli Lilly And Company	Buy	$656.7B	385.44%	47.85	25.91%
Johnson & Johnson	Buy	$426.7B	19.23%	18.97	25.0%
Novo Nordisk A/s	Buy	$248.7B	73.43%	14.51	35.61%
Abbvie Inc	Buy	$371.7B	129.02%	100.19	6.45%

Merck & Co. Dividend announcements

Merck & Co. Dividends September, 2025
In the quarter ending September,2025. Merck & Co. has declared dividend of $0.81

About Merck & Co. Inc.

Merck & Co., Inc. is an American multinational pharmaceutical company. The corporation conducts business outside of the United States and Canada under Merck Sharp & Dohme (MSD). It was founded as an American subsidiary of the German pharmaceutical company Merck & Co. in 1891. The company was given this name in honour of the Merck family. Merck acquired the Livogen trademark from Glaxo India for Rs 8 crore in 2000 - well over the market value. According to the company, Rofecoxib will be distributed in the Philippines via a co-marketing arrangement with the local pharmaceutical business Kopran. When Biochem Pharmaceutical Industries Ltd purchased Taloja in 2004, the firm spent a total of Rs 100 million, making it the most costly acquisition the company had made then. On March 27, 2002, a decision was made to rename the company from E Merck (India) Ltd to Merck Ltd, and the company was officially constituted on that day. This increased the firm's capacity for the manufacturing of Bulk Drugs by 33 tonnes in 2006, increasing the company's overall production capacity to 351 tonnes. In 2020, the pharmaceutical business will have six blockbuster medications or products with more than $1 billion in revenue. An antibody used to treat cancer is Keytruda, estimated to make $14.3 billion this year. Varivax is supposed to make $3.9 billion each, and Gardasil will make $1.4 billion each. Currently Merck & Co. Inc. has a market cap of $297.5 Billion. It has a P.E ratio of 21.66. The shares of Merck & Co. Inc. are trading at $84.13. .

Organization	Merck & Co.
Employees	73000
CEO	Mr. Robert M. Davis J.D.
Industry	Health Technology

Key Management of Merck & Co. Inc.

Name	Title
Mr. Robert M. Davis J.D.	Chairman, President & CEO
Ms. Caroline A. Litchfield	Executive VP & CFO
Ms. Betty D. Larson	Executive VP & Chief Human Resources Officer
Mr. Richard R. DeLuca Jr.	Executive VP & President of Merck Animal Health
Dr. Dean Y. Li M.D., Ph.D.	Executive VP & President of Merck Research Laboratories
Mr. Dalton E. Smart III	Senior VP of Finance, Principal Accounting Officer & Global Controller
Mr. David Michael Williams	Executive VP and Chief Information & Digital Officer
Mr. Peter Dannenbaum	Vice President of Investor Relations
Ms. Jennifer L. Zachary J.D.	Executive VP & General Counsel
Ms. Cristal N. Downing	Executive VP and Chief Communications & Public Affairs Officer

Important FAQs about investing in MRK Stock from India :

What is Merck & Co. share price today?

Merck & Co. share price today is $85.47 as on September 3, 2025 at 1:29 am IST at the close of the market. Merck & Co. share today touched a day high of $85.47 and a low of $84.45.

What is the 52 week high and 52 week low for Merck & Co. share?

Merck & Co. share touched a 52 week high of $120.30 and a 52 week low of $73.31. Merck & Co. stock price today i.e. September 3, 2025 at 1:29 am IST is closed at $85.47, lower by 28.95% versus the 52 week high.

How to invest in Merck & Co. Stock (MRK) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Merck & Co. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Merck & Co. Shares that will get you 0.0176 shares as per Merck & Co. share price of $85.47 per share as on September 3, 2025 at 1:29 am IST.

What is the minimum amount required to buy Merck & Co. Stock (MRK) from India?

Indian investors can start investing in Merck & Co. (MRK) shares with as little as ₹88.16 or $1 (as of September 03, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹881.60 in Merck & Co. stock (as per the Rupee-Dollar exchange rate as on September 03, 2025). Based on Merck & Co. share’s latest price of $85.47 as on September 3, 2025 at 1:29 am IST, you will get 0.1170 shares of Merck & Co.. Learn more about fractional shares .

What are the returns that Merck & Co. has given to Indian investors in the last 5 years?

Merck & Co. stock has given -1.31% share price returns and 20.13% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?